3285 related articles for article (PubMed ID: 30412495)
1. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
2. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
3. A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.
Porter T; Burnham SC; Savage G; Lim YY; Maruff P; Milicic L; Peretti M; Ames D; Masters CL; Martins RN; Rainey-Smith S; Rowe CC; Salvado O; Taddei K; Groth D; Verdile G; Villemagne VL; Laws SM
Front Aging Neurosci; 2018; 10():423. PubMed ID: 30620773
[TBL] [Abstract][Full Text] [Related]
4. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
5. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
6. Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals.
Xu Y; Vasiljevic E; Deming YK; Jonaitis EM; Koscik RL; Van Hulle CA; Lu Q; Carboni M; Kollmorgen G; Wild N; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Engelman CD
J Alzheimers Dis; 2023; 94(4):1587-1605. PubMed ID: 37482996
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
[TBL] [Abstract][Full Text] [Related]
12. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.
Racine AM; Clark LR; Berman SE; Koscik RL; Mueller KD; Norton D; Nicholas CR; Blennow K; Zetterberg H; Jedynak B; Bilgel M; Carlsson CM; Christian BT; Asthana S; Johnson SC
J Alzheimers Dis; 2016 Oct; 54(4):1395-1408. PubMed ID: 27589532
[TBL] [Abstract][Full Text] [Related]
13. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
14. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
15. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
16. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
Hohman TJ; Bell SP; Jefferson AL;
JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
19. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
20. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]